Abstracts tagged "Cohort Study"

Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
Abstract Number: 2215 • ACR Convergence 2023
Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy marques¹, Sofia Ramiro², Miranda Van Lunteren³, Rosalinde Stal³, Robert BM Landewé⁴, Marleen van de Sande⁵, Karen Minde Fagerli⁶, Inger Jorid Berg⁶, Maikel van oosterhout⁷, Sofia Exarchou⁸, Roberta Ramonda⁹, Désirée van der Heijde² and Floris Van Gaalen³, ¹Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁵Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ⁶Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands, ⁸Lund University, Åkarp, Sweden, ⁹University of Padova, Department of Rheumatology, Padova, Italy
Background/Purpose: Unacceptable diagnostic delay in axial Spondyloarthritis (axSpA) remains an issue. In 2008, the longitudinal SPondyloArthritis Caught Early (SPACE)-cohort started to assess the prevalence of…
Abstract Number: 2573 • ACR Convergence 2023
Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality
Michelle Ghebranious, Elena Joerns, Traci Adams and Trushil Shah, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) that manifests with interstitial pneumonia and features of autoimmunity while…
Abstract Number: 0471 • ACR Convergence 2023
Knowledge and Misconceptions About Contraception Among Individuals with Inflammatory Arthritis and Lupus-like Diseases
Caroline Siegel¹, Medha Barbhaiya², Lucy Masto¹, Amaya Smole¹, Bessie Stamm¹, Jonah Levine¹, Sarah Lieber², Lisa Mandl², Michael Lockshin² and Lisa Sammaritano², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Rheumatologists do not consistently provide contraceptive counseling for patients with systemic rheumatic disease (SRD). As contraception considerations may differ based on SRD, we compared…
Abstract Number: 0823 • ACR Convergence 2023
Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort
Burcu Aydemir¹, Orit Schieir², Marie-France Valois³, Lutfiyya Muhammad¹, Jing Song¹, dorothy Dunlop¹, Susan Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Glen Hazelwood⁷, Carol Hitchon⁸, Edward Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Diane Tin¹², Vivian Bykerk¹³, Yvonne Lee¹⁴ and Canadian Early Arthritis Cohort (CATCH) Investigators¹⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²McGill University, Montréal, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁶Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Manitoba, MB, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ¹³Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Northwestern University, Chicago, IL, ¹⁵CATCH, Winnipeg, MB, Canada
Background/Purpose: Despite taking strong immunosuppressive medications to control inflammation, many patients with rheumatoid arthritis (RA) continue to experience moderate to severe pain that does not…
Abstract Number: 1303 • ACR Convergence 2023
Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis
Audrey-Anne Couture¹, Nathalie Carrier², Hugues Allard-Chamard³, Sophie ROUX³, Patrick Liang³ and Gilles Boire³, ¹University of Montréal, Montréal, QC, Canada, ²CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ³Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Composite measures (e.g. SDAI) to assess Rheumatoid Arthritis (RA) disease activity incorporate patient (PGA) and evaluator (EGA) global assessments. EGA and PGA are often…
Abstract Number: 2261 • ACR Convergence 2023
Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study
Rangi Kandane-Rathnayake¹, Dominique Milea², Worawit Louthrenoo³, Alberta Hoi⁴, Vera Golder¹, Jiacai Cho⁵, Aisha Lateef⁵, Shue-Fen Luo⁶, Yeong-Jian J Wu⁷, Laniyati Hamijoyo⁸, Sargunan Sockalingam⁹, Zhanguo Li¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Masayoshi Harigai¹², Yasuhiro Katsumata¹², Madelynn Chan¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁵, Sean O’Neill¹⁶, Fiona Goldblatt¹⁷, Shereen Oon¹⁸, Xiaomeng Xu², Aldo Amador Navarro Rojas¹⁹, Sang-Cheol Bae²⁰, Chak Sing Lau²¹, Mandana Nikpour²² and Eric Morand²³, ¹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ²GlaxoSmithKline, Value Evidence and Outcomes, Singapore, Singapore, ³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁴Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ⁵National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁶Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹⁰Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹¹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁴St Vincent’s Hospital Melbourne, Department of Rheumatology, Melbourne, Australia, ¹⁵Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁶Department of Medicine, University of New South Wales, Kensington, Australia, ¹⁷Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ¹⁸University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ¹⁹GlaxoSmithKline, Medical Affairs, Singapore, Singapore, ²⁰Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²¹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ²³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: Up to 50% of patients with SLE develop irreversible organ damage within 10 years of diagnosis, and most experience recurrent disease flares of varying…
Abstract Number: 2588 • ACR Convergence 2023
Updated Analyses of Cancer Incidence and Risk Factors in a Large International SLE Cohort
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Murray Urowitz³, John G. Hanly⁴, Caroline Gordon⁵, Michelle Petri⁶, Ellen Ginzler⁷, Daniel Wallace⁸, Sang-Cheol Bae⁹, Juanita Romero-Diaz¹⁰, Mary Anne Dooley¹¹, Christine Peschken¹², David Isenberg¹³, Anisur Rahman¹⁴, Susan Manzi¹⁵, Soren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald van Vollenhoven¹⁸, Ola Nived¹⁹, Diane L. Kamen²⁰, Cynthia Aranow²¹, Jill Buyon²², Guillermo Ruiz-Irastorza²³, Francisco Sanchez-Guerrero²⁴, Dafna Gladman²⁵, Paul R. Fortin²⁶, Jennifer LF Lee²⁷, Luck Lukusa²⁷, Graciela S Alarcón²⁸, Joan Merrill²⁹, Kenneth Kalunian³⁰, Manuel Ramos-Casals³¹, Kristjan Steinsson³², Asad Zoma³³, Anca Askanase³⁴, Munther Khamashta³⁵, Ian Bruce³⁶, Murat Inanç³⁷ and Ann Clarke³⁸, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Northwestern University, Chicago, IL, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷SUNY Downstate Health Sciences University, Brooklyn, NY, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ¹⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹¹Raleigh Neurology Associates, Chapel Hill, NC, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³University College London, London, United Kingdom, ¹⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ¹⁶Rigshospitalet, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹⁹Department of Rheumatology, Institution of Clinical Sciences, Lund University Hospital, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²NYU Grossman School of Medicine, New York, NY, ²³Hospital Universitario Cruces, Barakaldo, Spain, ²⁴University Health Network/Sinai Health system, Toronto, ON, Canada, ²⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²⁶Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ²⁷RI-MUHC, Montreal, QC, Canada, ²⁸Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL, ²⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ³⁰University of California San Diego, La Jolla, CA, ³¹Hospital Clinic, Barcelona, Barcelona, Spain, ³²Landspitali University Hospital, Reykjavik, Iceland, ³³Lanarkshire Centre for Rheumatology and Hairmyres Hospital, East Kilbride, East Kilbride, United Kingdom, ³⁴Columbia University Medical Center, New York, NY, ³⁵GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ³⁶University of Manchester, Manchester, United Kingdom, ³⁷Istanbul University, Istanbul, Turkey, ³⁸University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…
Abstract Number: 0115 • ACR Convergence 2023
Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome
liang luo¹, Qingmeng Cai², xiangjun liu², Yuke Hou³ and Chun Li⁴, ¹Department of Chinese Medicine, the People's Hospital of Yubei District of Chongqing City, Chongqing, China; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People's Hospital, Xicheng District, Beijing, China, ³Peking University People's Hospital, Beijing, China, ⁴Peking University People’s Hospital, Beijing, China
Background/Purpose: Limited evidence exists regarding the long-term risk of thrombosis in patients with obstetric antiphospholipid syndrome (OAPS). This study aimed to investigate the clinical features…
Abstract Number: 0472 • ACR Convergence 2023
Contraception Choices in Individuals with Inflammatory Arthritis and Lupus-like Disease Differ Based on Diagnosis and Teratogen Use
Caroline Siegel¹, Medha Barbhaiya², Lucy Masto¹, Amaya Smole¹, Bessie Stamm¹, Jonah Levine¹, Sarah Lieber², Lisa Mandl², Michael Lockshin² and Lisa Sammaritano², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Individuals with systemic rheumatic disease (SRD) underutilize effective contraception even when prescribed teratogenic medications. As disease-related factors may impact contraception choice, we evaluated the…
Abstract Number: 0836 • ACR Convergence 2023
Vagotomy and Subsequent Risk of Rheumatoid Arthritis and Osteoarthritis: A Danish Register-Based Cohort Study
Matthew Baker¹, Dávid Nagy², Suzanne Tamang³, Erzsébet Horváth-Puhó² and Henrik Toft Sørensen², ¹Stanford University, Menlo Park, CA, ²Aarhus University Hospital, Aarhus, Denmark, ³Stanford University, Palo Alto, CA
Background/Purpose: Vagus nerve stimulation (VNS) is an emerging potential therapy for rheumatoid arthritis (RA). Given preliminary benefit observed with VNS in RA, we hypothesized that…
Abstract Number: 1333 • ACR Convergence 2023
Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset
YOSHIHIKO HOSHIDA¹, Atsuko Tsujii², SHIRO OHSHIMA³, YUKIHIKO SAEKI³, MASATO YAGITA⁴, TOMOYA MIYAMURA⁵, Masao Katayama⁶, TOMONORI KAWASAKI⁷, YASUSHI HIRAMATSU⁸, Hisaji Oshima⁹, TOSHIHIKO MURAYAMA¹⁰, SHINJI HIGA¹¹, KAZUYA KURAOKA¹², FUMINORI HIRANO¹³, KENJI ICHIKAWA¹⁴, MITSUTOSHI KUROSAWA¹⁵, HIROAKI SUZUKI¹⁵, NORIYUKI CHIBA¹⁶, TAKAO SUGIYAMA¹⁷, YUKO MINAMI¹⁸, HITOSHI NIINO¹⁹, ATSUSHI IHATA²⁰, IKUO SAITO²¹, AKIKO MITSUO²², TOSHITAKA MAEJIMA²³, ATSUHIRO KAWASHIMA²⁴, HIROSHI TSUTANI²⁵, KOICHIRO TAKAHI²⁶, TAKAHIKO KASAI²⁷, YOKO SHINNO²⁸, YOSHIRO TACHIYAMA²⁹, NORIHIRO TERAMOTO³⁰, KENICHI TAGUCHI³¹, SHINJI NAITO³², SHIGERU YOSHIZAWA³³, MASAHIRO ITO³⁴, YASUO SUENAGA³⁵, Shunsuke Mori³⁶, SHOICHI NAGAKURA³⁷, NORIE YOSHIKAWA³⁸, MITSUHARU NOMOTO³⁹, ATSUHISA UEDA⁴⁰, SHOUHEI NAGAOKA⁴¹, YUKIO TSUURA⁴², KEIGO SETOGUCHI⁴³, SHOJI SUGII⁴⁴, Asami Abe⁴⁵, TOSHIAKI SUGAYA⁴⁶, HIROYUKI SUGAHARA⁴⁷, MASAHIRO KOSETO⁴⁸, YASUO KUNUGIZA², NORISHIGE IIZUKA³, RYOSUKE YOSHIHARA⁴, HIROKI YABE⁵, TOMOAKI FUJISAKI⁶, EIICHI MORII⁷, MORISHIGE TAKESHITA⁸, MASAKAZU SATO⁹, KAZUYOSHI SAITO¹⁰, Kiyoshi Matsui¹¹, YASUHIKO TOMITA¹², HIROSHI FURUKAWA¹³ and Shigeto Tohma¹⁴, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ²Osaka Minami Medical Center, Kawachinagano City, Japan, ³National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, ⁴Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, ⁵NHO Kyushu Medical Center, Fukuoka, Japan, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ⁷NHO Nagoya Medical Center, Nagoya, Japan, ⁸Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁹National Tokyo Medical Center, Tokyo, Japan, ¹⁰NHO Kumamoto Medical Center, Kumamoto, Japan, ¹¹Daini Osaka Police Hospital, Osaka, Japan, ¹²NHO Kure Medical Center /Chugoku Cancer Center, Kure, Japan, ¹³NHO Asahikawa Medical Center, Asahikawa, Japan, ¹⁴Nissei hospital, Sapporo, Japan, ¹⁵NHO Hokkaido Cancer Center, Sapporo, Japan, ¹⁶NHO Morioka Medical Center, Morioka, Japan, ¹⁷NHO Shimoshizu Hospital, Yotsukaido, Japan, ¹⁸NHO Ibarakihigashi Hospital, Ibaraki, Japan, ¹⁹NHO Yokohama Medical Center, Yokohama, Japan, ²⁰National Hospital Organization Yokohama Medical Center, Yokohama, Japan, ²¹NHO Sagamihara Hospital, Sagamihara, Japan, ²²NHO Disaster Medical Center, Tachikawa, Japan, ²³NHO Shinshu Ueda Medical Center, Ueda, Japan, ²⁴NHO Kanazawa Medical Center, Kanazawa, Japan, ²⁵NHO Awara Hospital, Awara, Japan, ²⁶NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ²⁷Japan Red Cross Society Tokushima Hospital, Komatsushima, Japan, ²⁸NHO Okayama Medical Center, Okayama, Japan, ²⁹NHO Hiroshima Nishi Medical Center, Otake, Japan, ³⁰NHO Shikoku Cancer Center, Matsuyama, Japan, ³¹NHO Kyushu Cancer Center, Fukuoka, Japan, ³²NHO Ureshino Medical Center, Ureshino, Japan, ³³NHO Fukuoka Hospital, Fukuoka, Japan, ³⁴NHO Nagasaki Medical Center, Omura, Japan, ³⁵NHO Beppu Medical Center, Beppu, Japan, ³⁶NHO Kumamoto Saishun Medical Center, Koshi, Japan, ³⁷NHO Kumamoto Minami Hospital, Uki, Japan, ³⁸NHO Miyakonojo Medical Center, Miyakonojo, Japan, ³⁹NHO Kagoshima Medical Center, Kagoshima, Japan, ⁴⁰Yokohama City University Medical Center, Yokohama, Japan, ⁴¹Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴²Department of Pathology Yokosuka Kyosai Hospital, Yokosuka, Japan, ⁴³Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, ⁴⁴Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ⁴⁵Niigata Rheumatic Center, Shibata, Japan, ⁴⁶Fuchu Hospital, Izumi, Japan, ⁴⁷Sumitomo Hospital, Osaka, Japan, ⁴⁸Nippon Life Hospital, Osaka, Japan, ⁴⁹JCHO Hoshigaoka Medical Center, Hirakata, Japan, ⁵⁰Kishiwada City Hospital, Kishiwada, Japan, ⁵¹Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ⁵²Ako Central Hospital, Ako, Japan, ⁵³Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁵⁴Osaka University, Suita, Japan, ⁵⁵Fukuoka University, Fukuoka, Japan, ⁵⁶Kurashiki University of Science and the Arts, Kurashiki, Japan, ⁵⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵⁸Hyogo Medical University, Nishinomiya, Japan, ⁵⁹International University of Health and Welfare, Otawara City, Japan, ⁶⁰NHO Tokyo National Hospital, Kiyose, Japan, ⁶¹NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…
Abstract Number: 2281 • ACR Convergence 2023
Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study
Ke-Hung Lin¹, Tzu-Min Lin¹ and Chi-Ching Chang², ¹Taipei Medical University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disorder with high morbidity and mortality. Although CNS infections account for only 0.53–2.25% of all infections…
Abstract Number: 0128 • ACR Convergence 2023
Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: To evaluate the burden, longitudinal trends, and drivers of multimorbidity (MM; the presence of ≥2 morbidities) in patients with Systemic Sclerosis (SSc) vs. age-…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].